Patents and exclusivity rights currently prevent a generic Sprycel (dasatinib) from being manufactured in the United States. The first patent is expected to expire in April 2020, which would be the earliest date that a generic version might become available. However, certain circumstances, such as lawsuits or other patents for new uses of the drug, could delay this date.
Interested in a Discount on Sprycel?
Enter your email address to see if eMedTV's free DiscountRx service has a program that could help you save on your prescription(s).
Enter Your Email Address
Thank you!Thank you for your interest in DiscountRx from eMedTV. An email has been sent to the address you provided. Please follow the link within that email to see what offers may be available.
Sprycel® (dasatinib) is a prescription medication used to treat people with certain types of leukemia. It is taken by mouth once a day.
Sprycel is made by Bristol-Myers Squibb Company. It is currently protected from generic competition by patents and exclusivity rights that have not yet expired.
The first patent is set to expire in April 2020. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Sprycel uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Sprycel drug.
Dasatinib is the active ingredient in Sprycel, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.